Opioid Dependency
Conditions
Keywords
Buprenorphine tablet, Fast dissolving tablet, Opioid dependant patients
Brief summary
This is a multi-center, open-label, preference study of two sublingual formulations of buprenorphine HCl, in opioid-dependent patients on buprenorphine maintenance therapy. The objectives of this study are to evaluate the overall preference between two buprenorphine sublingual formulations, after a switch from the marketed tablet (Subutex®) to the new fast dissolving tablet (FDT), in opioid-dependent patients with buprenorphine 8 mg or 16 mg daily maintenance therapy.
Interventions
DRUGBuprenorphine hydrochloride marketed sublingual tablet (Subutex)
8 mg or 16 mg daily, sublingual route on Days 1 and 2
DRUGBuprenorphine hydrochloride fast dissolving tablet (FDT)
8 mg or 16 mg daily, sublingual route on Days 3, 4, and 5
Sponsors
Reckitt Benckiser LLC
Indivior Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must demonstrate their willingness to participate in the study and comply with its procedures by signing a written informed consent. * Patients must be at least (≥) 18 years of age, of either sex. * Patients treated for opioid dependence with Subutex®, with a stable dosage of 8 mg or 16 mg daily, and respecting the legal drug attachments. * Patients must understand and be able to adhere to the dosing and visit schedules, and agree to report concomitant medications / products and adverse events to the investigator or designee. * Women of childbearing potential (includes women who are less than one year postmenopausal and women who become sexually active) must be using or agree to use an acceptable method of birth control (e.g., hormonal contraceptive, medically prescribed IUD, condom in combination with spermicide) or be surgically sterile (e.g., hysterectomy or tubal ligation). * Women of childbearing potential should be counseled in the appropriate use of birth control while in this study. Women who are not currently sexually active must agree and consent to use one of the above-mentioned methods should they become sexually active while participating in the study. * Women of childbearing potential must have a urine pregnancy test with negative result within 2 weeks prior to inclusion (as performed under control of the investigator or designee).
Exclusion criteria
* Patients refusing to take the daily dose of the study medication under control in the center. * Patients unable to complete the evaluations. * Women who are pregnant or nursing. * Patients with a history of hypersensitivity to buprenorphine hydrochloride or any excipient of one of its formulations. * Patients with a current evidence of alcohol abuse. * Patients with severe respiratory dysfunction, severe hepatic dysfunction, acute alcohol intoxication or delirium tremens. * Initiation or increase in the dose, within the past 7 days or scheduled during the study, of a treatment with: * benzodiazepines, * other depressants of the central nervous system: other morphine derivatives (analgesics, antitussives), certain antidepressive agents, sedative H1 antihistamines, barbiturates, benzodiazepines, anxiolytics other than benzodiazepines, neuroleptics, clonidine and clonidine-like agents, * monoamine oxydase \[MAO\] inhibitors. * Patients who have any current evidence of clinically significant hematopoietic, metabolic, cardiovascular, immunologic, neurologic, hematological, gastrointestinal, hepatic, renal, psychiatric, cerebrovascular, or respiratory disease, or any other disorder which, in the judgment of the investigator, may interfere with the study evaluations or affect patient safety. * Patients who have used any investigational product within 30 days prior to enrollment. * Patients participating in another trial at the same time. * Patients intending to donate blood during the study or within 3 months after study completion. * Patients in the exclusion period of the Fichier National des personnes qui se prêtent à des recherches biomédicales sans bénéfice individuel direct (National Index of persons participating in biomedical researches without direct individual benefit, or National Index of volunteers). * Patients without Social Security number, or whose maximum annual compensation (3,800 €) has been exceeded.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Overall Preference Between Two Buprenorphine Sublingual Formulations, After a Switch From the Marketed Tablet (Subutex®) to the New Fast Dissolving Tablet (FDT), in Opioid-dependent Patients With Buprenorphine 8 mg or 16 mg Daily Maintenance Therapy. | Daily, Day 1 to Day 5 | Patient's overall satisfaction on Day 1 to Day 5 postdose. Marketed sublingual tablet (Marketed SL): Days 1 and 2; Fast dissolving tablet (FTD): Days 3, 4, and 5. Within 1 hour after complete dissolution of the tablet(s), overall satisfaction towards the study treatment was to be scored by the patient himself / herself using a 10-cm visual analogic scale (VAS) ranging from Not at all satisfied (score = 0) to Totally satisfied (score = 10). |
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Buprenorphine Hydrochloride 8 or 16 mg daily for 5 days; marketed sublingual tablet on Days 1 and 2, fast dissolving tablet (FDT) on Days 3, 4, and 5 | 52 |
| Total | 52 |
Baseline characteristics
| Characteristic | Buprenorphine Hydrochloride |
|---|---|
| Age, Continuous | 37.94 years STANDARD_DEVIATION 7.58 |
| Region of Enrollment France | 52 participants |
| Sex: Female, Male Female | 10 Participants |
| Sex: Female, Male Male | 42 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 3 / 52 |
| serious Total, serious adverse events | 0 / 52 |
Outcome results
Primary
The Overall Preference Between Two Buprenorphine Sublingual Formulations, After a Switch From the Marketed Tablet (Subutex®) to the New Fast Dissolving Tablet (FDT), in Opioid-dependent Patients With Buprenorphine 8 mg or 16 mg Daily Maintenance Therapy.
Patient's overall satisfaction on Day 1 to Day 5 postdose. Marketed sublingual tablet (Marketed SL): Days 1 and 2; Fast dissolving tablet (FTD): Days 3, 4, and 5. Within 1 hour after complete dissolution of the tablet(s), overall satisfaction towards the study treatment was to be scored by the patient himself / herself using a 10-cm visual analogic scale (VAS) ranging from Not at all satisfied (score = 0) to Totally satisfied (score = 10).
Time frame: Daily, Day 1 to Day 5
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Buprenorphine Hydrochloride | The Overall Preference Between Two Buprenorphine Sublingual Formulations, After a Switch From the Marketed Tablet (Subutex®) to the New Fast Dissolving Tablet (FDT), in Opioid-dependent Patients With Buprenorphine 8 mg or 16 mg Daily Maintenance Therapy. | Day 1 Marketed SL | 6.01 Score on a scale | Standard Deviation 2.42 |
| Buprenorphine Hydrochloride | The Overall Preference Between Two Buprenorphine Sublingual Formulations, After a Switch From the Marketed Tablet (Subutex®) to the New Fast Dissolving Tablet (FDT), in Opioid-dependent Patients With Buprenorphine 8 mg or 16 mg Daily Maintenance Therapy. | Day 2 Marketed SL | 5.91 Score on a scale | Standard Deviation 2.24 |
| Buprenorphine Hydrochloride | The Overall Preference Between Two Buprenorphine Sublingual Formulations, After a Switch From the Marketed Tablet (Subutex®) to the New Fast Dissolving Tablet (FDT), in Opioid-dependent Patients With Buprenorphine 8 mg or 16 mg Daily Maintenance Therapy. | Day 3 FTD | 7.73 Score on a scale | Standard Deviation 1.77 |
| Buprenorphine Hydrochloride | The Overall Preference Between Two Buprenorphine Sublingual Formulations, After a Switch From the Marketed Tablet (Subutex®) to the New Fast Dissolving Tablet (FDT), in Opioid-dependent Patients With Buprenorphine 8 mg or 16 mg Daily Maintenance Therapy. | Day 4 FTD | 7.75 Score on a scale | Standard Deviation 1.74 |
| Buprenorphine Hydrochloride | The Overall Preference Between Two Buprenorphine Sublingual Formulations, After a Switch From the Marketed Tablet (Subutex®) to the New Fast Dissolving Tablet (FDT), in Opioid-dependent Patients With Buprenorphine 8 mg or 16 mg Daily Maintenance Therapy. | Day 5 FTD | 7.72 Score on a scale | Standard Deviation 1.76 |
| Buprenorphine Hydrochloride | The Overall Preference Between Two Buprenorphine Sublingual Formulations, After a Switch From the Marketed Tablet (Subutex®) to the New Fast Dissolving Tablet (FDT), in Opioid-dependent Patients With Buprenorphine 8 mg or 16 mg Daily Maintenance Therapy. | Overall SL formulation | 5.96 Score on a scale | Standard Deviation 2.32 |
| Buprenorphine Hydrochloride | The Overall Preference Between Two Buprenorphine Sublingual Formulations, After a Switch From the Marketed Tablet (Subutex®) to the New Fast Dissolving Tablet (FDT), in Opioid-dependent Patients With Buprenorphine 8 mg or 16 mg Daily Maintenance Therapy. | Overall FTD formulation | 7.73 Score on a scale | Standard Deviation 1.74 |
p-value: <0.000195% CI: [1.35, 2.19]Analysis of variance